PMID: 2117641Sep 1, 1990Paper

Selective expansion of T cells expressing V beta 2 in toxic shock syndrome

The Journal of Experimental Medicine
Y ChoiB L Kotzin

Abstract

Infection with Staphylococcus aureus and the production of toxic shock syndrome toxin-1 (TSST-1) have been implicated in the pathogenesis of toxic shock syndrome. Previous in vitro studies have demonstrated that TSST-1 is a powerful but selective stimulator of human T cells, and that the majority of activated cells express the TCR V beta 2 gene segment. We therefore studied patients with toxic shock syndrome using a modification of the PCR to determine if expansion of V beta 2+ T cells is a marker of the in vivo disease process. Five of eight patients studied demonstrated markedly elevated levels of circulating V beta 2+ T cells, whereas none showed significantly elevated levels of T cells expressing other V beta gene segments. The results suggest that toxin-mediated T cell activation, which involves a large fraction of the human T cell repertoire, may be critical in the pathogenesis of this disease.

References

Nov 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·Y W ChoiJ Kappler
Jan 1, 1989·Reviews of Infectious Diseases·J Parsonnet
Dec 15, 1988·Annals of Internal Medicine·E R GaynorR I Fisher
Feb 12, 1987·The New England Journal of Medicine·B Beutler, A Cerami
Apr 1, 1971·Cellular Immunology·J SprentG F Mitchell
Apr 1, 1981·The Journal of Infectious Diseases·P M SchlievertR D Nishimura
Dec 18, 1980·The New England Journal of Medicine·J P DavisM LaVenture

❮ Previous
Next ❯

Citations

Sep 29, 1998·Arthritis and Rheumatism·D Y LeungH C Meissner
May 1, 1992·Journal of Clinical Immunology·C G Drake, B L Kotzin
Nov 1, 1995·Journal of Clinical Immunology·P M SchlievertY I Chi
Nov 1, 1995·Journal of Clinical Immunology·D Y LeungP M Schlievert
Nov 1, 1995·Journal of Clinical Immunology·D N PosnettA S Hodtsev
Jan 1, 1996·Springer Seminars in Immunopathology·J D Ohmen, R L Modlin
Jan 1, 1996·Springer Seminars in Immunopathology·D Y Leung
Feb 10, 1999·Medical Oncology·E Halapi
Jan 1, 1994·Immunologic Research·L I SakkasC D Platsoucas
Jan 1, 1991·Immunologic Research·L MayerY Li
Jul 28, 2005·European Journal of Pediatrics·Reiko OhashiYohnosuke Kobayashi
Jan 21, 1992·Journal of Immunological Methods·A BettinardiD Primi
Jan 1, 1995·Life Sciences·M A Blackman, D L Woodland
Jan 1, 1994·Molecular Aspects of Medicine·A MorrisS Young
Jul 1, 1996·Molecular Immunology·R MakidaD Y Leung
Dec 1, 1995·Human Immunology·D R Walser-KuntzJ J Goronzy
Jan 1, 1996·Human Immunology·U MahlknechtG E Dannecker
Jan 1, 1995·Trends in Cardiovascular Medicine·J C Burns, T Matsubara
Mar 9, 2004·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Hirotsugu KanoJun Abe
Dec 9, 2003·Journal of Immunological Methods·Christopher MacIsaacKumar Visvanathan
Feb 26, 1999·Journal of Immunological Methods·A VanderBorghtP Stinissen
Feb 12, 1997·Journal of the Neurological Sciences·A Khalili-ShiraziJ S Lanchbury
May 26, 1999·Infectious Disease Clinics of North America·S Sriskandan, J Cohen
Mar 21, 1998·Trends in Microbiology·C A Michie, J Cohen
Jun 22, 2001·Microbes and Infection·R P NovickA Ruzin
Feb 26, 2000·Molecular Medicine Today·J FraserT Proft
Apr 12, 2002·The Lancet Infectious Diseases·Martin Llewelyn, Jon Cohen
Sep 23, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Kyoung Soo KimWilliam Stohl
Nov 18, 2008·Biochemistry·Amanda J BrosnahanPatrick M Schlievert
Dec 3, 2005·Nature Reviews. Microbiology·Timothy J Foster

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.